Back to results
US 8,278,316 B2Granted
Aza pyridone analogs useful as melanin concentrating hormone receptor-1 antagonists
AssigneeBristol-Myers Squibb Company
InventorSaleem Ahmad
Life of this patent
Estimating the term…
Abstract
MCHR1 antagonists are provided having the following Formula I: wherein all of the variables are defined herein. Such compounds are useful for the treatment of MCHR1 mediated diseases, such as obesity, diabetes, IBD, depression, and anxiety.
Claims15
A compound having the following Formula I, or pharmaceutically acceptable salt thereof:
- wherein,
- A1 and A2 are independently C or N;
- E is C or N;
- Q1, Q2, and Q3 are independently C or N provided that at least one of Q1, Q2, and Q3 is N but not more than one of Q1, Q2, and Q3 is N;
- D1 is a bond, —CR8R9X—, —XCR8R9—, —CHR8CHR9—, —CR10═CR10′—, —C≡C—, or 1,2-cyclopropyl;
- X is O, S or NR11;
- R1, R2, and R3 are independently selected from the group consisting of hydrogen, halogen, substituted or unsubstituted C1 to C4 alkyl, substituted or unsubstituted C3 to C5 cycloalkyl, —CF3, —OCF3, —OR12, substituted or unsubstituted phenyl, substituted or unsubstituted cycloalkoxy, and —SR12;
- G is O, S or —NR15;
- D2 is substituted or unsubstituted C2 to C4 alkyl, substituted or unsubstituted substituted or unsubstituted C3 to C5 cycloalkyl, substituted or unsubstituted C3 to C5 cycloalkoxy, substituted or unsubstituted C2 to C3 alkyl-C3 to C5 cycloalkyl, substituted or unsubstituted C1 to C3 alkyl-substituted or unsubstituted C3 to C5 cycloalkoxy or when G is —NR15, G and D2 together may optionally form an azetidine, pyrrolidine or piperidine ring;
- Z1 and Z2 are independently hydrogen, substituted or unsubstituted C1 to C3 alkyl, substituted or unsubstituted C3 to C5 cycloalkyl, —OCH3, substituted or unsubstituted C3 to C5 cycloalkoxy, halo, —CF3, —OCONR14R14′, —CN, —CONR14R14′, —SOR12, —SO2R12, —NR14COR14′, —NR14CO2R14′, —CO2R12, NR14SO2R12 or —COR12;
- R5, R6, and R7 are independently selected from the group consisting of hydrogen, halogen, substituted or unsubstituted C1 to C4 alkyl, substituted or unsubstituted C3 to C5 cycloalkyl, substituted or unsubstituted C3 to C5 cycloalkoxy, —CF3, —SR12, —OCH3, —OCH2CH3, —CN, —CONR14R14′, SOR12, SO2R12, NR14COR14′, NR14CO2R12. CO2R12, NR14SO2R12 and —COR12;
- R8, R9, R10, R10′, R11 are independently hydrogen or —CH3;
- R12 is substituted or unsubstituted C1 to C4 alkyl or substituted or unsubstituted C3 to C5 cycloalkyl;
- R14 and R14′ are independently H, substituted or unsubstituted C1 to C3 alkyl, substituted or unsubstituted C3 to C5 cycloalkyl or R14 and R14′ together with the N to which they are attached form a ring having 4 to 7 atoms;
- and
- R15 is hydrogen or substituted or unsubstituted C1 to C4 alkyl.
13 more elements
A compound selected from the group consisting of:
- or a pharmaceutically acceptable salt of any of the preceding compounds.
Dependencies are inferred from the claim text.